Baidu
map

Radiology:也许PD患者出现视幻觉后预示着疾病的进展

2017-11-03 shaosai MedSci原创

为了通过分析全脑静息态功能连接来更好的理解帕金森病(PD)患者出现视幻觉(VHs)的病理生理机制,对合并VH的PD(PD +VH)患者、无VH的PD (PD - VH)患者和健康志愿者进行研究,并将结果发表在Radiology上。

为了通过分析全脑静息态功能连接来更好的理解帕金森病(PD)患者出现视幻觉(VHs)的病理生理机制,对合并VH的PD(PD +VH)患者、无VH的PD (PD - VH)患者和健康志愿者进行研究,并将结果发表在Radiology上。本研究共纳入了15例PD +VH的患者、40例PD - VH的患者和15名健康志愿者。测量全脑的47个感兴趣区和特定区域的功能连接性,并利用假发现率控制的线性模型进行多重对比。与对照组相比,PD患者的全脑平均功能连接性要明显减低,在PD + VH、PD - VH患者旁正中和枕叶区域减低(PD + VH、PD - VH全脑平均连接性分别为0.12 ± 0.01、0.14 ± 0.03,对照组为0.15 ± 0.04; P < .05)。在PD + VH组,9个额叶、颞叶、枕叶和纹状体区域显示功能连接性较对照组减低(在PD + VH、PD - VH和对照组中9个区域的平均连接性分别为0.12 ± 0.02、0.14 ± 0.03和 0.16 ± 0.04; P < .05)。静息态功能连接性与运动能力(r = 0.182; P = .184)没有显着相

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=258528, encodeId=d39725852841, content=学习学习学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=98, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzR8ylhYfiaoAUx2BsaYHVia1IKhG3Cg8CT84rBrn6iaVRkyAibJxBcLEXabOQ5p19vWgDe34ib5ErxNgx/0, createdBy=8a701629084, createdName=jihuaijun1112, createdTime=Sat Nov 04 07:03:26 CST 2017, time=2017-11-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=258521, encodeId=3a2f258521a3, content=好好好好很好很好, beContent=null, objectType=article, channel=null, level=null, likeNumber=105, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/08/29/bbc5cc0eed9b8d17623d2fd49dbdf19a.jpg, createdBy=79522135794, createdName=yjs木玉, createdTime=Sat Nov 04 06:56:02 CST 2017, time=2017-11-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=258474, encodeId=e81d2584e495, content=谢谢了.学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=100, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=30331616752, createdName=txqjm, createdTime=Sat Nov 04 00:15:45 CST 2017, time=2017-11-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=258456, encodeId=e18125845663, content=不错的文章值得推荐, beContent=null, objectType=article, channel=null, level=null, likeNumber=105, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=04f22055142, createdName=131****2916, createdTime=Fri Nov 03 23:07:24 CST 2017, time=2017-11-03, status=1, ipAttribution=)]
    2017-11-04 jihuaijun1112

    学习学习学习

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=258528, encodeId=d39725852841, content=学习学习学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=98, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzR8ylhYfiaoAUx2BsaYHVia1IKhG3Cg8CT84rBrn6iaVRkyAibJxBcLEXabOQ5p19vWgDe34ib5ErxNgx/0, createdBy=8a701629084, createdName=jihuaijun1112, createdTime=Sat Nov 04 07:03:26 CST 2017, time=2017-11-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=258521, encodeId=3a2f258521a3, content=好好好好很好很好, beContent=null, objectType=article, channel=null, level=null, likeNumber=105, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/08/29/bbc5cc0eed9b8d17623d2fd49dbdf19a.jpg, createdBy=79522135794, createdName=yjs木玉, createdTime=Sat Nov 04 06:56:02 CST 2017, time=2017-11-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=258474, encodeId=e81d2584e495, content=谢谢了.学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=100, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=30331616752, createdName=txqjm, createdTime=Sat Nov 04 00:15:45 CST 2017, time=2017-11-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=258456, encodeId=e18125845663, content=不错的文章值得推荐, beContent=null, objectType=article, channel=null, level=null, likeNumber=105, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=04f22055142, createdName=131****2916, createdTime=Fri Nov 03 23:07:24 CST 2017, time=2017-11-03, status=1, ipAttribution=)]
    2017-11-04 yjs木玉

    好好好好很好很好

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=258528, encodeId=d39725852841, content=学习学习学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=98, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzR8ylhYfiaoAUx2BsaYHVia1IKhG3Cg8CT84rBrn6iaVRkyAibJxBcLEXabOQ5p19vWgDe34ib5ErxNgx/0, createdBy=8a701629084, createdName=jihuaijun1112, createdTime=Sat Nov 04 07:03:26 CST 2017, time=2017-11-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=258521, encodeId=3a2f258521a3, content=好好好好很好很好, beContent=null, objectType=article, channel=null, level=null, likeNumber=105, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/08/29/bbc5cc0eed9b8d17623d2fd49dbdf19a.jpg, createdBy=79522135794, createdName=yjs木玉, createdTime=Sat Nov 04 06:56:02 CST 2017, time=2017-11-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=258474, encodeId=e81d2584e495, content=谢谢了.学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=100, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=30331616752, createdName=txqjm, createdTime=Sat Nov 04 00:15:45 CST 2017, time=2017-11-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=258456, encodeId=e18125845663, content=不错的文章值得推荐, beContent=null, objectType=article, channel=null, level=null, likeNumber=105, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=04f22055142, createdName=131****2916, createdTime=Fri Nov 03 23:07:24 CST 2017, time=2017-11-03, status=1, ipAttribution=)]
    2017-11-04 txqjm

    谢谢了.学习

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=258528, encodeId=d39725852841, content=学习学习学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=98, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzR8ylhYfiaoAUx2BsaYHVia1IKhG3Cg8CT84rBrn6iaVRkyAibJxBcLEXabOQ5p19vWgDe34ib5ErxNgx/0, createdBy=8a701629084, createdName=jihuaijun1112, createdTime=Sat Nov 04 07:03:26 CST 2017, time=2017-11-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=258521, encodeId=3a2f258521a3, content=好好好好很好很好, beContent=null, objectType=article, channel=null, level=null, likeNumber=105, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/08/29/bbc5cc0eed9b8d17623d2fd49dbdf19a.jpg, createdBy=79522135794, createdName=yjs木玉, createdTime=Sat Nov 04 06:56:02 CST 2017, time=2017-11-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=258474, encodeId=e81d2584e495, content=谢谢了.学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=100, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=30331616752, createdName=txqjm, createdTime=Sat Nov 04 00:15:45 CST 2017, time=2017-11-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=258456, encodeId=e18125845663, content=不错的文章值得推荐, beContent=null, objectType=article, channel=null, level=null, likeNumber=105, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=04f22055142, createdName=131****2916, createdTime=Fri Nov 03 23:07:24 CST 2017, time=2017-11-03, status=1, ipAttribution=)]
    2017-11-03 131****2916

    不错的文章值得推荐

    0

相关资讯

Radiology:功能性脑连接及帕金森病病变严重程度的关系

帕金森病(PD)又名震颤麻痹,是最常见的神经退行性疾病之一。流行病学显示,患病率为15~328/10万人口,>65岁人群约1%;发病率为10~21/10万人口/年。PD病因及发病机制尚未明确,可能与社会因素、药物因素、患者因素等有关。PD病理改变为:中脑黑质致密部、蓝斑神经元色素脱失,黑质色素变淡及出现路易小体。PD神经生化改变为:中脑黑质致密部、蓝斑神经元脱失致上述部位及其神经末梢处多巴胺(DA

Radiology:对于有视力改变的老年人,你是否会想到是帕金森病的前驱临床表现呢?

帕金森病又称特发性帕金森病(idiopathic Parkinson's disease,PD),简称Parkinson病,也称为震颤麻痹(paralysis agitans,shaking palsy),是中老年人常见的神经系统变性疾病,也是中老年人最常见的锥体外系疾病。人口老龄化后,人口基数也越来越大。研究人员对PD有更深地理解,为了评价新诊PD患者在首次用药后视力改变情况。并将研究结果发表在

老树开新花!金刚烷胺新用途获FDA批准

帕金森病(PD)是一种常见的慢性神经退行性疾病,伴随治疗药物的使用,产生的运动障碍也成为了众多帕金森患者的困扰。克服运动障碍对于PD患者来说,不仅是身体的解放,更是心理上的一种解放。帕金森病人的福音来了。近日,美国食品和药物管理局(FDA)批准金刚烷胺(amantadine,曾用名ADS-5102)缓释胶囊用于治疗在接受左旋多巴治疗的PD患者的运动障碍。

Lancet:艾塞那肽对帕金森病的治疗效果。

Exenatide(艾塞那肽),胰高血糖素样肽-1(GLP-1)受体激动剂,对帕金森病的临床潜伏期模型有神经保护作用,艾塞那肽对确诊帕金森病患者有怎样的效果呢?

The Lancet:糖尿病药物或可用于治疗帕金森病

伦敦大学学院领导的一项新研究发现,通常用于治疗糖尿病的药物艾塞那肽可能具有改善帕金森病的潜力。该研究发表The Lancet期刊上,研究发现,帕金森病患者每周注射艾塞那肽,持续1年后运动能力出现改善。

Mayo Clin Proc:肉毒毒素能否改善帕金森病震颤和患者感觉?

2017年9月,发表在《Mayo Clin Proc》上的一项双盲、安慰剂-对照、交叉试验,调查了肉毒毒素对帕金森病(PD)震颤的治疗效果。试验结果表明:在临床范围内,经个性化方式注射肉毒毒素(IncoA)能改善PD震颤和患者感觉,手无力发生率显着较低。

Baidu
map
Baidu
map
Baidu
map